We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma.
- Authors
Ho-Shin Gwak; Gi Taek Yee; Chul-Kee Park; Jin Wook Kim; Yong-Kil Hong; Seok-Gu Kang; Jeong Hoon Kim; Ho Jun Seol; Tae-Young Jung; Jong Hee Chang; Heon Yoo; Jeong-Hyun Hwang; Se-Hyuk Kim; Bong Jin Park; Sun-Chul Hwang; Min Su Kim; Seon-Hwan Kim; Eun-Young Kim; Ealmaan Kim; Hae Yu Kim
- Abstract
Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.
- Subjects
TEMOZOLOMIDE; DRUG efficacy; OLIGODENDROGLIOMAS; TUMOR treatment; RETROSPECTIVE studies; THERAPEUTICS
- Publication
Journal of Korean Neurosurgical Society, 2013, Vol 54, Issue 6, p489
- ISSN
2005-3711
- Publication type
Article
- DOI
10.3340/jkns.2013.54.6.489